DermTech Cash Conversion Cycle vs Free Cash Flow Per Share Analysis

DMTK Stock

USD 0.50 0.07 12.28%

DermTech financial indicator trend analysis is much more than just examining DermTech latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether DermTech is a good investment. Please check the relationship between DermTech Cash Conversion Cycle and its Free Cash Flow Per Share accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.

Cash Conversion Cycle vs Free Cash Flow Per Share

Cash Conversion Cycle vs Free Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of DermTech Cash Conversion Cycle account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have pay attention.

The correlation between DermTech's Cash Conversion Cycle and Free Cash Flow Per Share is -0.75. Overlapping area represents the amount of variation of Cash Conversion Cycle that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of DermTech, assuming nothing else is changed. The correlation between historical values of DermTech's Cash Conversion Cycle and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Conversion Cycle of DermTech are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Cash Conversion Cycle i.e., DermTech's Cash Conversion Cycle and Free Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

-0.75

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Cash Conversion Cycle

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Most indicators from DermTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into DermTech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.Selling General Administrative is expected to rise to about 46 M this year, although the value of Issuance Of Capital Stock will most likely fall to about 5 M.

DermTech fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Total Liab	Long Term Investments	Total Current Assets	Common Stock	Property Plant Equipment	Net Debt	Net Receivables	Net Invested Capital
Total Assets		0.73	0.72	0.97	0.82	-0.62	0.72	0.85	0.61	0.28	0.71	0.45	0.87	0.28	0.72	0.05	0.53	0.67	0.59	-0.13	0.87	0.28	0.83	-0.64	0.87	0.3
Other Current Liab	0.73		0.97	0.58	0.88	-0.96	0.74	0.64	0.32	-0.19	0.95	0.49	0.7	-0.19	0.94	-0.21	0.92	0.95	0.95	-0.35	0.71	-0.19	0.85	-0.23	0.91	-0.05
Total Current Liabilities	0.72	0.97		0.58	0.9	-0.95	0.8	0.69	0.23	-0.25	0.94	0.36	0.74	-0.26	0.91	-0.38	0.86	0.89	0.9	-0.51	0.75	-0.26	0.88	-0.31	0.91	-0.02
Total Stockholder Equity	0.97	0.58	0.58		0.76	-0.46	0.65	0.85	0.57	0.37	0.58	0.42	0.86	0.37	0.61	0.12	0.35	0.5	0.41	-0.06	0.86	0.37	0.78	-0.73	0.77	0.39
Net Tangible Assets	0.82	0.88	0.9	0.76		-0.86	0.78	0.87	0.22	-0.17	0.92	0.46	0.89	-0.18	0.93	-0.18	0.69	0.75	0.75	-0.34	0.89	-0.18	1.0	-0.57	0.93	0.2
Retained Earnings	-0.62	-0.96	-0.95	-0.46	-0.86		-0.63	-0.53	-0.28	0.2	-0.96	-0.42	-0.58	0.22	-0.93	0.31	-0.93	-0.88	-0.95	0.42	-0.59	0.22	-0.82	0.1	-0.81	0.11
Accounts Payable	0.72	0.74	0.8	0.65	0.78	-0.63		0.81	0.06	-0.27	0.64	0.35	0.85	-0.28	0.68	-0.45	0.48	0.6	0.55	-0.6	0.85	-0.28	0.79	-0.63	0.86	-0.14
Cash	0.85	0.64	0.69	0.85	0.87	-0.53	0.81		0.11	-0.15	0.65	0.31	0.99	-0.15	0.68	-0.1	0.33	0.51	0.42	-0.28	0.98	-0.15	0.9	-0.89	0.86	0.41
Non Current Assets Total	0.61	0.32	0.23	0.57	0.22	-0.28	0.06	0.11		0.85	0.33	0.36	0.14	0.84	0.25	0.29	0.42	0.39	0.4	0.24	0.14	0.84	0.21	0.07	0.28	0.03
Non Currrent Assets Other	0.28	-0.19	-0.25	0.37	-0.17	0.2	-0.27	-0.15	0.85		-0.15	0.17	-0.16	1.0	-0.2	0.4	-0.08	-0.13	-0.11	0.43	-0.17	1.0	-0.16	0.09	-0.18	0.07
Other Assets	0.71	0.95	0.94	0.58	0.92	-0.96	0.64	0.65	0.33	-0.15		0.46	0.68	-0.16	0.94	-0.19	0.91	0.9	0.94	-0.31	0.69	-0.16	0.9	-0.24	0.87	0.07
Long Term Debt	0.45	0.49	0.36	0.42	0.46	-0.42	0.35	0.31	0.36	0.17	0.46		0.35	0.15	0.64	0.47	0.44	0.42	0.43	0.4	0.35	0.15	0.46	-0.14	0.44	-0.3
Cash And Short Term Investments	0.87	0.7	0.74	0.86	0.89	-0.58	0.85	0.99	0.14	-0.16	0.68	0.35		-0.16	0.73	-0.1	0.39	0.58	0.47	-0.3	1.0	-0.16	0.9	-0.84	0.91	0.36
Common Stock Total Equity	0.28	-0.19	-0.26	0.37	-0.18	0.22	-0.28	-0.15	0.84	1.0	-0.16	0.15	-0.16		-0.21	0.42	-0.09	-0.14	-0.13	0.44	-0.16	1.0	-0.17	0.08	-0.18	0.11
Common Stock Shares Outstanding	0.72	0.94	0.91	0.61	0.93	-0.93	0.68	0.68	0.25	-0.2	0.94	0.64	0.73	-0.21		-0.04	0.83	0.85	0.87	-0.19	0.74	-0.21	0.91	-0.31	0.88	0.02
Short Term Investments	0.05	-0.21	-0.38	0.12	-0.18	0.31	-0.45	-0.1	0.29	0.4	-0.19	0.47	-0.1	0.42	-0.04		-0.2	-0.13	-0.23	0.97	-0.11	0.42	-0.16	0.01	-0.17	0.33
Non Current Liabilities Total	0.53	0.92	0.86	0.35	0.69	-0.93	0.48	0.33	0.42	-0.08	0.91	0.44	0.39	-0.09	0.83	-0.2		0.94	0.99	-0.27	0.4	-0.09	0.65	0.14	0.72	-0.18
Inventory	0.67	0.95	0.89	0.5	0.75	-0.88	0.6	0.51	0.39	-0.13	0.9	0.42	0.58	-0.14	0.85	-0.13	0.94		0.96	-0.26	0.59	-0.14	0.71	-0.07	0.86	0.0
Total Liab	0.59	0.95	0.9	0.41	0.75	-0.95	0.55	0.42	0.4	-0.11	0.94	0.43	0.47	-0.13	0.87	-0.23	0.99	0.96		-0.32	0.49	-0.13	0.72	0.05	0.78	-0.13
Long Term Investments	-0.13	-0.35	-0.51	-0.06	-0.34	0.42	-0.6	-0.28	0.24	0.43	-0.31	0.4	-0.3	0.44	-0.19	0.97	-0.27	-0.26	-0.32		-0.31	0.44	-0.32	0.16	-0.35	0.24
Total Current Assets	0.87	0.71	0.75	0.86	0.89	-0.59	0.85	0.98	0.14	-0.17	0.69	0.35	1.0	-0.16	0.74	-0.11	0.4	0.59	0.49	-0.31		-0.16	0.91	-0.83	0.92	0.35
Common Stock	0.28	-0.19	-0.26	0.37	-0.18	0.22	-0.28	-0.15	0.84	1.0	-0.16	0.15	-0.16	1.0	-0.21	0.42	-0.09	-0.14	-0.13	0.44	-0.16		-0.17	0.08	-0.18	0.11
Property Plant Equipment	0.83	0.85	0.88	0.78	1.0	-0.82	0.79	0.9	0.21	-0.16	0.9	0.46	0.9	-0.17	0.91	-0.16	0.65	0.71	0.72	-0.32	0.91	-0.17		-0.62	0.92	0.23
Net Debt	-0.64	-0.23	-0.31	-0.73	-0.57	0.1	-0.63	-0.89	0.07	0.09	-0.24	-0.14	-0.84	0.08	-0.31	0.01	0.14	-0.07	0.05	0.16	-0.83	0.08	-0.62		-0.55	-0.49
Net Receivables	0.87	0.91	0.91	0.77	0.93	-0.81	0.86	0.86	0.28	-0.18	0.87	0.44	0.91	-0.18	0.88	-0.17	0.72	0.86	0.78	-0.35	0.92	-0.18	0.92	-0.55		0.16
Net Invested Capital	0.3	-0.05	-0.02	0.39	0.2	0.11	-0.14	0.41	0.03	0.07	0.07	-0.3	0.36	0.11	0.02	0.33	-0.18	0.0	-0.13	0.24	0.35	0.11	0.23	-0.49	0.16

Click cells to compare fundamentals

DermTech Account Relationship Matchups

DermTech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	18.2M	69.8M	248.3M	202.1M	121.9M	82.3M
Other Current Liab	2.7M	2.8M	6.3M	11.4M	8.7M	9.1M
Total Current Liabilities	5.7M	5.4M	12.2M	15.6M	13.4M	14.1M
Total Stockholder Equity	12.5M	63.5M	229.7M	132.4M	57.2M	64.2M
Net Tangible Assets	12.5M	63.5M	229.7M	132.4M	152.2M	159.8M
Retained Earnings	(91.1M)	(126.4M)	(206.4M)	(323.0M)	(423.9M)	(402.7M)
Accounts Payable	1.6M	1.6M	2.9M	2.4M	1.5M	1.2M
Cash	15.4M	24.2M	176.9M	77.8M	36.7M	33.4M
Non Current Assets Total	1.1M	2.9M	15.5M	66.0M	60.2M	30.5M
Non Currrent Assets Other	12.4M	84K	167K	168K	3.5M	3.3M
Other Assets	84K	167K	3.2M	3.7M	4.2M	4.4M
Cash And Short Term Investments	15.4M	63.8M	225.3M	126.2M	55.9M	48.7M
Common Stock Total Equity	4.1M	1K	2K	3K	2.7K	2.6K
Common Stock Shares Outstanding	7.0M	17.0M	28.9M	30.0M	32.6M	34.3M
Short Term Investments	12.4M	39.5M	48.4M	48.4M	19.1M	18.2M
Liabilities And Stockholders Equity	18.2M	69.8M	248.3M	202.1M	121.9M	82.0M
Capital Surpluse	103.6M	189.8M	436.2M	456.2M	524.6M	550.8M
Inventory	35K	104K	480K	1.8M	1.0M	1.1M
Other Current Assets	1.1M	1.5M	3.2M	3.9M	2.3M	1.3M
Other Stockholder Equity	103.6M	120.1M	436.2M	456.2M	480.9M	505.0M
Total Liab	5.7M	6.3M	18.6M	69.7M	64.8M	68.0M
Property Plant And Equipment Gross	977K	2.7M	12.3M	6.4M	60.5M	63.5M
Total Current Assets	17.2M	66.9M	232.8M	136.0M	61.8M	51.8M
Accumulated Other Comprehensive Income	(239K)	(1K)	(124K)	(774K)	178K	186.9K
Common Stock	4.1M	1K	2K	3K	2.7K	2.6K
Property Plant Equipment	977K	2.7M	12.3M	6.4M	7.3M	7.7M
Net Debt	(15.4M)	(23.9M)	(169.0M)	(21.9M)	17.7M	18.5M
Net Invested Capital	12.5M	63.5M	229.7M	132.4M	57.2M	101.0M
Net Working Capital	11.4M	61.5M	220.6M	120.4M	48.3M	72.5M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as DermTech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether DermTech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if DermTech Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Dermtech Stock. Highlighted below are key reports to facilitate an investment decision about Dermtech Stock:

How To Invest In DermTech

Details

Is DermTech Stock a good investment?

Details

What is DermTech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DermTech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy DermTech Stock please use our How to buy in DermTech Stock guide.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for DermTech Stock analysis

When running DermTech's price analysis, check to measure DermTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DermTech is operating at the current time. Most of DermTech's value examination focuses on studying past and present price action to predict the probability of DermTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DermTech's price. Additionally, you may evaluate how the addition of DermTech to your portfolios can decrease your overall portfolio volatility.

	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine

Is DermTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DermTech. If investors know DermTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DermTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.09)

Revenue Per Share

0.465

Quarterly Revenue Growth

0.106

Return On Assets

(0.39)

Return On Equity

(1.22)

The market value of DermTech is measured differently than its book value, which is the value of DermTech that is recorded on the company's balance sheet. Investors also form their own opinion of DermTech's value that differs from its market value or its book value, called intrinsic value, which is DermTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DermTech's market value can be influenced by many factors that don't directly affect DermTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between DermTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if DermTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DermTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

DermTech Cash Conversion Cycle vs Free Cash Flow Per Share Analysis

Cash Conversion Cycle vs Free Cash Flow Per Share

Cash Conversion Cycle vs Free Cash Flow Per Share Correlation Analysis

Correlation Coefficient

Cash Conversion Cycle

Free Cash Flow Per Share

DermTech fundamental ratios Correlations

DermTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

DermTech fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for DermTech Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant Equipment	+ 1.0	Net Tangible Assets
Common Stock Total Equity	+ 1.0	Non Currrent Assets Other
Common Stock	+ 1.0	Non Currrent Assets Other
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.99	Cash

Other Assets	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Other Current Liab
Total Liab	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Total Current Liabilities
Non Current Liabilities Total	- 0.93	Retained Earnings
Common Stock Shares Outstanding	- 0.93	Retained Earnings